Lilly now Lilly - Search News

Novo, Lilly

Bloomberg L.P. · 8h

Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.

Lilly Claims Key Weight Loss Victory Over Novo in Head-to-Head Study

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in stronger weight loss than semaglutide.

Business Insider · 8h

Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trial

EST Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trialDon't Miss our Black Friday Offers:Unlock your

8hon MSN

Eli Lilly Just Got a Bundle of Good News: Time to Buy?

Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has ...

Is Now a Good Time to Buy the Dip in Eli Lilly Stock?

However, Lilly's shares (like pharmaceutical companies in general) tend to be quite volatile. As I write this, the stock ...

6h

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

The Motley Fool on MSN14d

Is It Time to Sell Eli Lilly and Pfizer Stocks?

Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid. Eli Lilly now ranks as the largest drugmaker in the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results